A33-radionuclides

N/A

Report date: 2025/11/24 11:49:15

Base Information

Drug NameA33-radionuclides
Drug Alias NamehA33-90YCDP-833
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized +[6] 
Mechanisms of ActionCell surface A33 antigen inhibitors
TargetsCell surface A33 antigen
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanySwitzerland
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCelltech
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelltechLudwig Institute For Cancer ResearchNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A